MX2021007043A - Anticuerpos antiperiostina y usos de estos. - Google Patents

Anticuerpos antiperiostina y usos de estos.

Info

Publication number
MX2021007043A
MX2021007043A MX2021007043A MX2021007043A MX2021007043A MX 2021007043 A MX2021007043 A MX 2021007043A MX 2021007043 A MX2021007043 A MX 2021007043A MX 2021007043 A MX2021007043 A MX 2021007043A MX 2021007043 A MX2021007043 A MX 2021007043A
Authority
MX
Mexico
Prior art keywords
periostin antibodies
periostin
antibodies
block
function
Prior art date
Application number
MX2021007043A
Other languages
English (en)
Inventor
Johan Fransson
Arif Jetha
Aj Robert Mcgray
Joanne Hulme
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of MX2021007043A publication Critical patent/MX2021007043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen en la presente anticuerpos que bloquean la función de la periostina. También se describen en la presente sus usos para tratar el cáncer y modificar las propiedades inmunitarias de los tumores.
MX2021007043A 2018-12-14 2019-12-13 Anticuerpos antiperiostina y usos de estos. MX2021007043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779996P 2018-12-14 2018-12-14
US201962899075P 2019-09-11 2019-09-11
PCT/IB2019/001307 WO2020121059A1 (en) 2018-12-14 2019-12-13 Anti-periostin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2021007043A true MX2021007043A (es) 2021-08-11

Family

ID=71075443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007043A MX2021007043A (es) 2018-12-14 2019-12-13 Anticuerpos antiperiostina y usos de estos.

Country Status (20)

Country Link
US (1) US20220010003A1 (es)
EP (1) EP3894439A4 (es)
JP (2) JP2022513228A (es)
KR (1) KR20210108972A (es)
CN (1) CN113631571A (es)
AU (1) AU2019395887A1 (es)
BR (1) BR112021010634A2 (es)
CA (1) CA3120059A1 (es)
CL (1) CL2021001297A1 (es)
CO (1) CO2021007444A2 (es)
CR (1) CR20210310A (es)
DO (1) DOP2021000113A (es)
EC (1) ECSP21043288A (es)
IL (1) IL283890A (es)
JO (1) JOP20210144A1 (es)
MA (1) MA54472A (es)
MX (1) MX2021007043A (es)
PE (1) PE20211962A1 (es)
SG (1) SG11202103849TA (es)
WO (1) WO2020121059A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001985A2 (pt) * 2019-09-11 2022-05-10 Boehringer Ingelheim Io Canada Inc Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina
KR20240038198A (ko) 2022-09-15 2024-03-25 한남대학교 산학협력단 인슐린 분비 베타세포 분화 유도 항체 및 이를 유효성분으로 포함하는 대사성 질환 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20090028793A1 (en) * 2006-02-22 2009-01-29 Philogen Spa Vascular Tumor Markers
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
NZ740686A (en) * 2015-09-18 2021-12-24 Arch Oncology Inc Therapeutic cd47 antibodies

Also Published As

Publication number Publication date
PE20211962A1 (es) 2021-10-04
CL2021001297A1 (es) 2022-01-07
SG11202103849TA (en) 2021-05-28
ECSP21043288A (es) 2021-09-30
CR20210310A (es) 2021-11-24
EP3894439A1 (en) 2021-10-20
IL283890A (en) 2021-07-29
JP2023139243A (ja) 2023-10-03
BR112021010634A2 (pt) 2021-11-16
CA3120059A1 (en) 2020-06-18
MA54472A (fr) 2022-03-23
JP2022513228A (ja) 2022-02-07
CO2021007444A2 (es) 2021-09-30
US20220010003A1 (en) 2022-01-13
EP3894439A4 (en) 2022-11-30
JOP20210144A1 (ar) 2023-01-30
WO2020121059A1 (en) 2020-06-18
DOP2021000113A (es) 2021-09-30
KR20210108972A (ko) 2021-09-03
AU2019395887A1 (en) 2021-05-20
CN113631571A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021012133A (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
EP3964527A3 (en) Combination therapy for cancer
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2021015495A (es) Composiciones y métodos para tratar cáncer.
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
IL289663A (en) Claudin 18 antibodies and methods for cancer treatment
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2020006297A (es) Variantes de cd19.
CR20210310A (es) Anticuerpos antiperiostina y usos de estos
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
EA201990370A1 (ru) Терапия рака, связанная с crebbp
MX2021003262A (es) Metodos de tratamiento.
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
MX2021003265A (es) Metodos de tratamiento.